From 1 July 2025, two new items for 177Lutetium (Lutetium) prostate specific membrane antigen (PSMA) therapy (16050 and 16055) will be listed on the Medicare Benefits Schedule for the treatment of patients with progressive or symptomatic metastatic castrate-resistant prostate cancer, where prior treatment has failed.
A new whole-body PSMA positron emission tomography diagnostic imaging item (61528) will also be listed to determine a patient’s suitability to undergo Lutetium PSMA therapy.
Further information is provided in the Factsheet below: